2018
DOI: 10.1021/acs.jmedchem.8b00322
|View full text |Cite
|
Sign up to set email alerts
|

Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists

Abstract: Cachexia and muscle wasting are very common among patients suffering from cancer, chronic obstructive pulmonary disease, and other chronic diseases. Ghrelin stimulates growth hormone secretion via the ghrelin receptor, which subsequently leads to increase of IGF-1 plasma levels. The activation of the GH/IGF-1 axis leads to an increase of muscle mass and functional capacity. Ghrelin further acts on inflammation, appetite, and adipogenesis and for this reason was considered an important target to address catabol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(12 citation statements)
references
References 42 publications
0
12
0
Order By: Relevance
“…A high-throughput screening (HTS) approach on AstraZeneca’s library, followed by hit to lead generation, led to the discovery of a series of indane diamides behaving as GHS-R1a partial agonists ( 8 – 10 ) with submicromolar potency ( Figure 8 A). 59 From a subsequent lead optimization strategy, an interesting modulation of the biological profile from partial to full agonism was obtained. In particular, an extensive SAR study led to the identification of the potent druglike GHS-R1a full agonist 11 (EC 50 = 1.6 nM; E max = 89%) ( Figure 8 A), 59 which was devoid of significant hERG channel inhibition.…”
Section: Medicinal Chemistry Of Ghs-r1a Ligandsmentioning
confidence: 99%
See 1 more Smart Citation
“…A high-throughput screening (HTS) approach on AstraZeneca’s library, followed by hit to lead generation, led to the discovery of a series of indane diamides behaving as GHS-R1a partial agonists ( 8 – 10 ) with submicromolar potency ( Figure 8 A). 59 From a subsequent lead optimization strategy, an interesting modulation of the biological profile from partial to full agonism was obtained. In particular, an extensive SAR study led to the identification of the potent druglike GHS-R1a full agonist 11 (EC 50 = 1.6 nM; E max = 89%) ( Figure 8 A), 59 which was devoid of significant hERG channel inhibition.…”
Section: Medicinal Chemistry Of Ghs-r1a Ligandsmentioning
confidence: 99%
“… 59 From a subsequent lead optimization strategy, an interesting modulation of the biological profile from partial to full agonism was obtained. In particular, an extensive SAR study led to the identification of the potent druglike GHS-R1a full agonist 11 (EC 50 = 1.6 nM; E max = 89%) ( Figure 8 A), 59 which was devoid of significant hERG channel inhibition. This compound showed adequate pharmacokinetic (PK) profile, displaying long half-life and limited brain penetration and increased insulin-like growth factor-1 (IGF-1) secretion in dogs.…”
Section: Medicinal Chemistry Of Ghs-r1a Ligandsmentioning
confidence: 99%
“…Indanes and its derivatives are found in various natural products and biological active molecules, [84] particularly, the aminoindane derivatives are pharmaceutically important candidates [85] . To incorporate the trifluoromethyl group in aminoindane scaffold, recently Sharma and coworkers reported the first synthesis of the 1‐(trifluoromethyl)‐1 H ‐inden‐3‐amine scaffolds 139 using Rh(III)‐catalysed [3+2] C−H annulation reaction of benzimidates 138 with β ‐(trifluoromethyl)‐ α , β ‐unsaturated ketones 3 .…”
Section: Carbocyclic Synthesismentioning
confidence: 99%
“…The NMR spectra match the literature precedence. 47 1,2-Dimesityldiselane. N-Bromosuccinimide (2.2 g, 1 equiv) and selenium metal powder (1.2 g 1.2 equiv) were added to a roundbottom flask, and then MeCN (∼60 mL, 0.2 M) was added to the mixture and stirred at 60 °C for 10 min.…”
Section: Scheme 5 Proposed Catalytic Cyclementioning
confidence: 99%